177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study

Author(s): Amar U. Kishan, MD^1,2; Luca F. Valle, MD^1,3; Holly Wilhalme, MS⁴; Carol Felix, BS¹; Rejah Nabong, BS⁵; Jesus E. Juarez-Casillas, MS, BS¹; Kevin Flores, BS¹; T. Martin Ma, MD, PhD⁶; Vinicius Ludwig, MD⁵; Mariko Nakayama, MD^5,7; Zachary Ells, BS⁵; Magnus Dahlbom, PhD⁵; Michael Lauria, PhD¹; Catherine Meyer, PhD⁵; Minsong Cao, PhD⁸; Joanne B. Weidhaas, MD, PhD¹; Donatello Telesca, PhD⁹; Kristen McGreevy, PhD⁹; Nicholas G. Nickols, MD, PhD^1,3; Danielle Karasik, BS¹; Sophia Parmisano, BS¹; T. Vincent Basehart, BS¹; Wayne Brisbane, MD²; Leonard Marks, MD²; Matthew B. Rettig, MD^3,10; Robert E. Reiter, MD²; Paul C. Boutros, PhD^2,11; Martin Allen-Auerbach, MD⁵; Johannes Czernin, MD⁵; Michael L. Steinberg, MD¹; Jeremie Calais, MD, PhD⁵;

Source: DOI: 10.1200/JCO-25-01553

Dr. Maen Hussein's Thoughts

For our radiation oncology colleagues, the addition of PSMA-directed therapy prior to stereotactic body radiation therapy (SBRT) improved progression-free survival (PFS) in patients with oligometastatic prostate cancer. Two cycles of PSMA-directed therapy were administered before SBRT.

PURPOSE

Progression after metastasis-directed therapy via stereotactic body radiotherapy (SBRT) for oligorecurrent hormone-sensitive prostate cancer (orHSPC) is common. We aimed to assess whether the addition of neoadjuvant prostate-specific membrane antigen (PSMA)–targeting radioligand therapy to SBRT would improve outcomes.

METHODS

The LUNAR trial was a single-center, randomized, open-label, controlled phase II trial conducted the University of California, Los Angeles. Eligible participants had orHSPC as determined by the presence of one to five lesions identified on PSMA positron emission tomography/computed tomography (PET/CT). After stratifying by stage (N1/M1a v M1b) and lesion count (1 v 2-3 v 4-5), we randomly assigned patients 1:1 to receive SBRT to all lesions or two cycles of 177Lu-PNT2002 (6.8 GBq/cycle, 2 weeks apart) followed by SBRT to all lesions. The primary end point was progression-free survival (PFS), defined by PSMA PET/CT, salvage hormonal therapy, or death. PSMA PET/CT was acquired systematically prostate-specific antigen progression and/or 12 months after SBRT. All analyses were done in the intention-to-treat population. The study is registered with ClinicalTrials.gov (identifier: NCT05496959).

RESULTS

From September 2, 2022, to November 9, 2023, 92 patients were randomly assigned (SBRT n = 47 and 177Lu + SBRT n = 45), with 87 evaluable patients (SBRT n = 42 and 177Lu + SBRT n = 45). a median follow-up of 22 months, the addition of 177Lu to SBRT significantly improved PFS (17.6 months [95% CI 15 months to not reached] v 7.4 months [95% CI, 6.0 to 13.5 months]; hazard ratio, 0.37 [95% CI, 0.22 to 0.61], P < .0001). The only grade 3 adverse events were lymphopenia (two patients [4.8%] in the SBRT group and three patients [6.7%] in the 177Lu + SBRT group). Prognostic biomarkers for PFS were identified.

CONCLUSION

Compared with SBRT alone, the addition of 177Lu-PNT2002 to SBRT significantly improved PFS in patients with orHSPC without an attendant increase in toxicity.

Author Affiliations

¹Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA; ²Department of Urology, University of California, Los Angeles, Los Angeles, CA; ³Greater Los Angeles VA Medical Center, Los Angeles, CA; ⁴Department of Medicine Statistical Core, University of California, Los Angeles, Los Angeles, CA; ⁵Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA; ⁶Department of Radiation Oncology, University of Washington, Seattle, WA; ⁷Department of Radiological Sciences, University of California, Los Angeles, Los Angeles, CA; ⁸Department of Radiation Oncology, University of San Francisco, San Francisco, CA; ⁹Department of Biostatistics, University of California, Los Angeles, Los Angeles, CA; ¹⁰Department of Medicine, University of California, Los Angeles, Los Angeles, CA; ¹¹Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA

Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer

Overall survival was 78.9% in the combination group compared with 69.5% in the leuprolide-alone group (HR 0.60). Enzalutamide monotherapy resulted in an overall survival of 73.1%, which was not statistically significant. We were already aware of the progression-free survival benefit; now we have overall survival data. This case was also presented in the MOC questions, where the correct answer was to add enzalutamide for a patient with a rising PSA on an LHRH agonist without imaging evidence of disease.

Metformin Active Surveillance Trial in Low-Risk Prostate Cancer

Metformin did not significantly reduce the risk of disease progression compared with active surveillance in patients with low-risk prostate cancer.

Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials

A new MMAI-derived digital pathology biomarker was trained and prospectively validated across multiple NRG/RTOG phase III trials, including RTOG 9202 (N=1,192), to predict which high-risk/locally advanced PCa patients benefit from LT-ADT vs ST-ADT with RT. In the overall cohort, LT-ADT reduced DM (17% vs 26% at 15 years) and DDM (15% vs 23% at 15 years), but this benefit was limited to biomarker-positive patients (DM: 19% vs 33%; DDM: 19% vs 30%), with no advantage seen in biomarker-negative patients (DM: 11% vs 11%; DDM: 9% vs 10%). This tool could allow about a third of our "high-risk" patients to avoid two extra years of ADT without compromising metastasis outcomes, while ensuring we intensify for those most likely to benefit. In short, this is a practical step toward personalizing ADT duration and sparing toxicity for a significant subset of our patients.

European Study of Prostate Cancer Screening — 23-Year Follow-up

A 13% reduction in mortality was observed in the screening group, with an improved harm-benefit ratio. For every 456 men screened, one prostate cancer death was prevented. It is an easy and inexpensive test, though concerns remain regarding unnecessary biopsies and overtreatment.

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

Pasritamig was administered to patients who had received a median of four prior lines of systemic therapy. It was well tolerated, with manageable adverse events, making it suitable for outpatient administration. The treatment showed a median radiographic progression-free survival of 7.85 months, and 14 out of 33 participants achieved a ≥50% reduction in baseline PSA levels. So, stay tuned.